Kratz, Johannes R.
Li, Jack Z.
Tsui, Jessica
Lee, Jen C.
Ding, Vivianne W.
Rao, Arjun A.
Mann, Michael J.
Chan, Vincent
Combes, Alexis J.
Krummel, Matthew F.
Jablons, David M.
Funding for this research was provided by:
UCSF Bakar ImmunoX Initiative
Helen Diller Family Comprehensive Cancer Center
American Association for Thoracic Surgery Foundation
Article History
Received: 13 July 2021
Accepted: 24 November 2021
First Online: 8 December 2021
Competing interests
: JRK reports consulting fees from Razor Genomics, consulting fees from and stock ownership in Oncocyte Corp, and patent rights for a prognostic assay for early-stage lung cancer with royalties paid. MJM, and DMJ report consulting fees from and ownership interest in Razor Genomics, consulting fees from and stock ownership in Oncocyte Corp, and patent rights for a prognostic assay for early-stage lung cancer with royalties paid. JZL, JT, JCL, WVD, AAR, AJC, VC, and MFK declare no potential conflict of interest.